The large-scale, international HER-EAGLE study revealed a global HER2-positivity rate of 10%–20% in GC, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with positive in situ hybridization (ISH) (Kim et al., 2018). Here, ERBB2 is linked to gastric cancer.